Impact Factor 4.019

The world's most-cited Microbiology journal

Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Microbiol. | doi: 10.3389/fmicb.2018.03128

Respiratory Syncytial Virus in Hematopoietic Cell Transplant Recipients and Hematologic Malignancy Patients

  • 1University of Texas MD Anderson Cancer Center, United States

In the United States and other western nations, respiratory syncytial virus (RSV) is one of the most commonly encountered respiratory viruses among patients who have been diagnosed with a hematological malignancy or who have undergone a stem cell transplant. Multiple studies have been performed to evaluate the complications associated with RSV infections. Other studies have evaluated therapeutic agents and strategies in which these agents can be used. There have also been numerous reports of outbreaks in bone marrow transplant units and oncology wards, where infection control measures have been invaluable in controlling the spread of disease. However, despite these novel approaches, RSV continues to be lethal in immunocompromised populations. In this review, we discuss the incidence of RSV infections, risk factors associated with progression from upper respiratory tract infection to lower respiratory tract infection, other complications and outcomes (including mortality), management strategies, and prevention strategies in patients with hematologic malignancy and hematopoetic cell transplant recipients.

Keywords: Respiratory syncitial virus, hematological malignancies (HM), Ribavrin, Hematopoeitic stem cell transplantation, respiratory virus, Stem cell transplant (SCT)

Received: 06 Sep 2018; Accepted: 04 Dec 2018.

Edited by:

Thomas Lion, St. Anna Children’s Cancer Research Institute (CCRI), Austria

Reviewed by:

Joanna Kirman, University of Otago, New Zealand
Masfique Mehedi, University of North Dakota, United States  

Copyright: © 2018 Khawaja and Chemaly. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Prof. Roy F. Chemaly, University of Texas MD Anderson Cancer Center, Houston, United States,